IGFBPL1: A Promising Drug Target and Biomarker for Insulin-Like Growth Factor-Binding Protein-Related Diseases

Target Name: IGFBPL1

NCBI ID: G347252

IGFBPL1

IGFBPL1: A Promising Drug Target and Biomarker for Insulin-Like Growth Factor-Binding Protein-Related Diseases

The insulin-like growth factor (IGF) family plays a crucial role in regulating cellular growth, differentiation, and survival. The IGF family consists of five transmembrane proteins: IGF-1, IGF-2, IGF-3, IGF-4, and IGF-5. Of these, IGF-4 (IGFBP-4) is the most abundant and has the highest molecular weight, which makes it an attractive drug target in the context of insulin-like growth factor (IGF) biology. IGFBP-4 is a protein that can interact with various IGFs, including IGF-1, IGF-2, IGF-3, and IGF-5. It has been implicated in various physiological processes, including cell survival, angiogenesis, and inflammation. In this article, we will discuss the IGFBP-4 protein, its functions, and its potential as a drug target and biomarker.

Structure and Function

The IGFBP-4 protein is a 21-kDa transmembrane protein that contains an N-terminal extracellular domain, a transmembrane region, and an C-terminal intracellular domain. It has a molecular weight of 62.1 kDa and a calculated pI of 6.5. IGFBP-4 is a monomer and has been shown to have four distinct isoforms, which differ in their N-terminal and C-terminal extensions.

The IGFBP-4 protein plays a critical role in the regulation of cellular processes, including cell growth, apoptosis, angiogenesis, and inflammation. One of the most significant functions of IGFBP-4 is its ability to interact with various IGFs, including IGF-1, IGF-2, IGF-3, and IGF-5. This interaction between IGFBP-4 and IGFs is critical for the regulation of cellular processes, including cell survival, angiogenesis, and inflammation.

IGFBP-4 has been shown to play a role in various physiological processes, including cell survival and angiogenesis. For example, studies have shown that IGFBP-4 can promote the survival of cancer cells by inhibiting cell apoptosis and increasing cell proliferation. Additionally, IGFBP-4 has been shown to promote the formation of blood vessels in various tissues, including the skin, heart, and liver. This process is critical for the development and maintenance of tissues and organs.

IGFBP-4 has also been implicated in the regulation of inflammation. Studies have shown that IGFBP-4 can regulate the production of pro-inflammatory cytokines, including TNF-伪, IL-1, and IL-6. This regulation of cytokines is critical for the regulation of immune responses and inflammation.

Drug Targeting and Biomarker

The potential of IGFBP-4 as a drug target is based on its ability to interact with various IGFs and its role in the regulation of cellular processes, including cell growth, apoptosis, angiogenesis, and inflammation. Several studies have shown that IGFBP-4 can be targeted with small molecules, including inhibitors of tyrosine kinase activity and inhibitors of IGF-1 signaling.

One of the most promising strategies for targeting IGFBP-4 is the use of small molecules that can inhibit its tyrosine kinase activity. This approach is based on the idea that tyrosine kinase activity is critical for the regulation of IGFBP-4 function. Several studies have shown that inhibitors of tyrosine kinase activity can effectively inhibit IGFBP-4 function, including its ability to promote cell survival and angiogenesis.

Another approach to targeting IGFBP

Protein Name: Insulin Like Growth Factor Binding Protein Like 1

Functions: IGF-binding proteins prolong the half-life of IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs in cell culture. They alter the interaction of IGFs with their cell surface receptors (By similarity). May be a putative tumor suppressor protein

The "IGFBPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFBPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets